Until as recently as this year, most of the treatment options for treating symptoms of late stage MS involved injecting one or many drugs. Fingolimod Multiple Sclerosis finally gained FDA approval on September 22, 2010. Fingolimod MS pills could mark a turning point in the treatment of Multiple Sclerosis. Pills are much more convenient and tolerable for patients, and could mean they are more likely to stay on their treatment plans. Fingolimod Multiple Sclerosis oral medication is marketed under the name Gilenya and targets the relapsing-remitting MS that is defined as relapsing episodes, usually progressively worse, followed by a period where the symptoms either completely or partially disappear. It both slows the progression of disability and reduces the frequency of relapses.
The most frequent side effects reported with the Fingolimod MS pills were headache, diarrhea, back pain, influenza, liver enzyme level elevation and cough.
